The successful construction and functional examination of anti-EGFR CAR-T cells targeting EGFR-expressing ESCC cells provide a preclinical basis for the application of CAR-T cell immunotherapy in ESCC. This evidence concerns the gene EGFR and esophageal squamous cell carcinoma.